News Archive

2016

September

Media Release / Sep 28, 2016

Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine

Read More
Media Release / Sep 28, 2016

Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges

Read More
Media Release / Sep 23, 2016

Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions

Read More
Media Release / Sep 23, 2016

Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients

Read More
Media Release / Sep 22, 2016

Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs

Read More
NIBR researcher Jennifer Allport-Anderson looks into a microscope
Story / Sep 08, 2016

A cellular drama at the heart of a researcher’s family

Jennifer Allport-Anderson hunts for cardiac cures.

Read More
Media Release / Sep 08, 2016

Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience

Read More
Media Release / Sep 03, 2016

Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups

Read More

August

Media Release / Aug 31, 2016

AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment

Read More
Media Release / Aug 30, 2016

FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases

Read More

Pages

Related Links

Annual Report 2015

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More

Contact Media Relations

For media and journalist inquiries, please contact the Novartis Corporate Media Relations office by email or telephone.

Central Media Line:
Phone: +41 61 324 2200